Results 251 to 260 of about 70,786 (313)

Protein glycosylation in lung cancer from a mass spectrometry perspective

open access: yesMass Spectrometry Reviews, Volume 45, Issue 3, Page 455-475, May/June 2026.
ABSTRACT Lung cancer is a severe disease for which better diagnostic and therapeutic approaches are urgently needed. Increasing evidence implies that aberrant protein glycosylation plays a crucial role in the pathogenesis and progression of lung cancer.
Mirjam Balbisi   +2 more
wiley   +1 more source

Carrier screening in the reproductive setting—Are there medical implications for the heterozygote?—A guide for clinicians

open access: yesPregnancy, Volume 2, Issue 3, May 2026.
Abstract Carrier screening for genetic conditions performed preconception or during pregnancy allows identification of fetal risk for inherited autosomal recessive and X‐linked conditions. The goal is to identify at‐risk patients/couples and offer them reproductive options such as preimplantation genetic diagnosis, prenatal testing, or targeted newborn
Emily B. Rosenfeld   +5 more
wiley   +1 more source

Sialic acid [PDF]

open access: yesScience-Business eXchange, 2014
openaire   +1 more source

Mucin Type Drives Composition and Mucin Glycan Degradation of an In Vitro Synthetic Microbial Community

open access: yesEnvironmental Microbiology, Volume 28, Issue 5, May 2026.
The human gut outer mucus layer hosts specific microbes. Using a synthetic mucin glycan‐degrading microbial community to mimic this mucosal microbiome, we show that mucin type affects microbial community composition, glycan degradation and metabolite production.
Maryse D. Berkhout   +5 more
wiley   +1 more source

CD24 in Melanoma: Biomarker, Innate Immune Checkpoint and Emerging Therapeutic Target

open access: yesExperimental Dermatology, Volume 35, Issue 5, May 2026.
ABSTRACT Immune checkpoint inhibitors have transformed the treatment of advanced melanoma, yet many patients develop primary or acquired resistance. Although most work has focused on adaptive checkpoints (PD‐1 and CTLA‐4), accumulating evidence implicates innate immune suppression and stem‐like, drug‐resistant melanoma cell states.
Claudia Lasalle   +6 more
wiley   +1 more source

Gamma‐irradiated Newcastle disease virus: an alternative inactivated oncolytic virotherapy

open access: yesImmunology &Cell Biology, Volume 104, Issue 5, Page 473-484, May‐June 2026.
To overcome biological risks associated with using live NDV as an oncolytic therapy, we developed gamma‐NDV as a safer alternative. Using a murine model for skin cancer, we show that intratumor administration of gamma‐NDV outperformed live‐NDV in terms of reducing tumor growth and improving overall animal survival. Abstract Newcastle disease virus (NDV)
Eve V Kennedy   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy